This article is more than 5 years old. Information may no longer be current.
Zoledronic acid improved bone health in patients with osteoporosis
Click Here to Manage Email Alerts
Use of zoledronic acid for the treatment of osteoporosis enhanced bone mineral density and reduced bone turnover in patients, according to results.
Overall, 154 adult patients (149 women) with osteoporosis were treated between January 2008 and December 2011 with a once-yearly 5 mg dose of zoledronic acid intravenously. The percentage change in bone mineral density (BMD) from baseline after 12 months of zoledronic acid treatment was the primary efficacy endpoint.
Results showed 66.2% of patients had fractures prior to zoledronic acid treatment and approximately 85% of patients received at least two zoledronic acid infusions. Researchers found an 11% improvement in BMD from baseline at 12 months following zoledronic acid treatment and a 20.7% improvement at 48 months. Mean beta-C-telopeptide had a significant reduction at all time points from 12 months to 36 months, according to results. Researchers noted 16 patients experienced new clinical fractures, with a single fracture occurring in 12 patients. – by Casey Tingle
Disclosure: Hsieh’s institution received a grant from Novartis (Taiwan) Co. Ltd.
Click Here to Manage Email Alerts